EP2650008
Notkun gagndræpra peptíðhemla JNK boðmiðlunartaugabrautar til að meðhöndla mismunandi krabbameinssjúkdóma
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
2.6.2009EP published:
17.12.2014EP application number:
13002793.1
EP translation filed:
19.1.2015Grant published:
15.2.2015EPO information:
European Patent Register
Max expiry date:
1.6.2029Expiry date:
1.6.2017
Title:
Use of cell permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various cancer diseases
Timeline
Today
2.6.2009EP application
17.12.2014EP Publication
19.1.2015Translation submitted
15.2.2015Registration published
1.6.2017Expires
Owner
Name:
Xigen Inflammation Ltd.Address:
Arch. Makariou III 195 Neocleous House, 3030, Limassol, CY
Inventor
Name:
Bonny, ChristopheAddress:
Avenches, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/EP2008/004341Date:
30.5.2008Country:
WO
Classification
Categories:
A61K 38/01, A61K 38/03, A61K 38/04, A61P 9/00, A61P 11/00, A61P 17/00, A61P 25/00, A61P 31/12, A61P 37/00
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 22.6.2015
Expires: 1.6.2016
Payer: Guðjón Styrkársson, hrl.
Number: 8
Paid: 20.6.2016
Expires: 1.6.2017
Payer: Guðjón Styrkársson, hrl.